CDSCO clarifies concerns raised regarding BA/BE, FDCs, INDs, license/permission for import/manufacture of new drugs or clinical trial, sub acute toxicity report study and stability data for COPP

CDSCO clarifies concerns raised regarding BA/BE, FDCs, INDs, license/permission for import/manufacture of new drugs or clinical trial, sub acute toxicity report study and stability data for COPP

by comtideging1971 | Feb 27, 2020 | OPS, Pharmaceuticals, states